NCT05875727View on ClinicalTrials.gov

A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.

PHASE3CompletedINTERVENTIONAL
Enrollment

405

Participants

Timeline

Start Date

August 16, 2023

Primary Completion Date

October 2, 2023

Study Completion Date

October 2, 2023

Conditions
Pneumococcal Disease
Interventions
BIOLOGICAL

20-valent pneumococcal conjugate vaccine

One dose of 20vPnC will be administered intramuscularly.

Trial Locations (8)

110075

Aakash Healthcare Private Limited, New Delhi

305001

Jawahar Lal Nehru Hospital, Ajmer

Jawahar Lal Nehru Medical College, Ajmer

395002

Nirmal Hospital Pvt Ltd., Surat

411043

Bharati Vidyapeeth (Deemed to be University) Medical College Hospital & Research Centre, Pune

560060

BGS Global Institute of Medical Sciences (BGSGIMS), Bangalore

560074

RajaRajeswari Medical College and Hospital, Bangalore

RajaRajeswari Medical College and Hospital, Bengaluru

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05875727 - A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India. | Biotech Hunter | Biotech Hunter